Abiraterone and enzalutamide both target androgen signalling but work through different mechanisms. Combining them is not recommended because it substantially increases the risk of liver toxicity and hypertension. Any combination therapy should only be pursued in a clinical trial setting or under specialist supervision.
There is no routine requirement to discontinue abiraterone before elective surgery, but the surgical team should be informed of the medication due to its effects on blood pressure, electrolytes, and wound healing. Adjustments to glucocorticoid dosing may be necessary peri-operatively.
A high-fat meal can double the drug’s absorption, potentially raising the incidence of side effects. For consistent exposure, take the tablet on an empty stomach, at least one hour before or two hours after any food.
Fluid retention associated with mineralocorticoid excess may lead to a modest increase in body weight. This is usually reversible with diuretics, blood-pressure control, and appropriate glucocorticoid cover.
Routine full-dose laboratory monitoring is not needed before every single dose, but regular checks of liver enzymes, potassium, and blood pressure are essential-typically every 2-4 weeks early in therapy and then at longer intervals if stable.
Some patients experience modest changes in lipid profiles, particularly increases in LDL cholesterol. Lipid panels should be performed periodically, and statin therapy may be considered if levels become elevated.
Yes, but keep the medication in its original labelled container, carry a copy of the prescription, and be prepared to show the prescription at customs if asked. For flights longer than 8 hours, bring a small cooler pack if ambient temperatures may exceed 30 °C.
If you remember within 12 hours, take the missed tablet; otherwise, skip it and continue with the next scheduled dose. Doubling up is unnecessary and may increase side-effect risk.
Because abiraterone can raise blood pressure and cause fluid overload, patients with pre-existing cardiac conditions require more intensive monitoring and may need antihypertensive or diuretic therapy. Cardiologists should be involved in the care plan where appropriate.
Abiraterone acetate is the generic name, and the 250 mg tablet is marketed under the brand name Zytiga in the UK. Generic equivalents may become available after patent expiry; they contain the same active ingredient and dosage strength.
Abiraterone is a medication used in the treatment of advanced prostate cancer. The active ingredient in Abiraterone is abiraterone acetate, an oral androgen biosynthesis inhibitor. In the United Kingdom it is available as a 250 mg pill (tablet) and is prescribed by specialist oncologists under the supervision of the Medicines and Healthcare products Regulatory Agency (MHRA). It is marketed in the UK under the brand name Zytiga.
Abiraterone belongs to the therapeutic class often described as oncology support agents because it is used alongside other cancer-directed therapies to control disease progression. The medication is supplied only by prescription (Rx) and requires careful monitoring of hormonal and metabolic parameters.
Abiraterone acetate is a pro-drug that is rapidly converted in the gut and liver to abiraterone, the active metabolite. Abiraterone blocks the enzyme CYP17A1 (17α-hydroxylase/17,20-lyase), which is essential for the production of androgens (testosterone, dihydrotestosterone) in the adrenal glands, testes, and prostate tumour tissue.
By inhibiting CYP17A1, abiraterone dramatically reduces circulating androgen levels, depriving prostate cancer cells of the hormones they need to grow. The drug’s effect is systemic rather than limited to the testes, which explains its efficacy in castration-resistant disease where tumours have adapted to low testosterone environments.
Key pharmacological points:
Abiraterone is approved in the United Kingdom for the following indications, as detailed in the MHRA product licence and NICE technology appraisal guidance:
In both settings, abiraterone is prescribed alongside ongoing continuous androgen-deprivation therapy (ADT), usually in the form of a luteinising hormone-releasing hormone (LHRH) agonist or antagonist, to maintain castrate levels of testosterone.
Current peer-reviewed literature does not support routine off-label use of abiraterone for conditions other than prostate cancer. Investigational studies have explored its role in:
These uses remain experimental, are not approved by the UK regulatory agencies, and would require enrolment in a clinical trial or a specialist’s compassionate-use prescription.
Disclaimer: Off-label use of abiraterone must be undertaken only under the direct supervision of a qualified oncologist, with a clear risk-benefit assessment and appropriate monitoring.
If a patient is unsure about any medication, supplement, or herb they are taking, they should disclose all products to their healthcare professional before starting abiraterone.
No dose adjustments are required for age, weight, or renal function, but the liver function must be within acceptable limits before initiation and monitored throughout therapy.
Effective and safe use of abiraterone relies on regular clinical and laboratory assessment:
Patients should be instructed to contact their healthcare team immediately if they experience symptoms such as severe abdominal pain, sudden weight gain, persistent vomiting, or visual changes.
This article provides educational information about Abiraterone and is not a substitute for professional medical advice. Treatment decisions, including the use of unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
